European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>Sumitomo has offered $22.75/share in cash, 27% premium, for the 48% stake it doesn't hold in Myovant, whose Board has rejected the offer and is open to negotiate.</li>
<li>The sell-side forecasts peak sales of over $2 billion for Orgovyx and Myfembree. Myovant also has a co-marketing deal with Pfizer could be worth $3.8 billion in milestones.</li>
<li>My TP is $22.84 (in line with consensus and the offer price). The market certainly believes that Sumitomo could be preparing a sweetened offer. Will Orgovyx become a blockbuster?</li>
</ul>


Sumitomo has offered $22.75/share in cash, 27% premium, for the 48% stake it doesn't hold in Myovant, whose Board has rejected the offer and is open to negotiate.
The sell-side forecasts peak sales of over $2 billion for Orgovyx and Myfembree. Myovant also has a co-marketing deal with Pfizer could be worth $3.8 billion in milestones.
My TP is $22.84 (in line with consensus and the offer price). The market certainly believes that Sumitomo could be preparing a sweetened offer. Will Orgovyx become a blockbuster?


United States

Sio Gene Therapies, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops gene therapies that transform the treatment of serious neurodegenerative diseases. Sio Gene Therapies serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sio Gene Therapies (AXONEUR E1 EQUITY)

Sumitomo/Myovant: Minorities Takeout

The question is whether Orgovyx could become a blockbuster. The market certainly thinks so, there may be both further upside potential in the...

Jesus Rodriguez Aguilar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)